📰 Development Programs News
Page 166 - Development Programs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Development Programs. Real-time updates on events, politics, business and more.
May 19, 2023
By Lewis Pennock for Dailymail.Com and Matthew Phelan Senior Science Reporter for Dailymail.Com
May 18, 2023
For generations, the students of Brenau University have whispered about the legend of Agnes, the ghost that allegedly haunts the seats of the historic Pearce Auditorium.
May 17, 2023
Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage
May 15, 2023
TACOMA, Wash., May 15, 2023 /PRNewswire/ -- TrueBlue is proud to announce that it was recognized as one of Americas Best Employers for Diversity by Forbes for the second consecutive year, ranking... | May 15, 2023
May 11, 2023
StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research report released on Sunday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Acorda Therapeutics Stock Performance ACOR opened at $0.85 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.16 and […]
May 4, 2023
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic
May 4, 2023
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA® in the U.S. for adult patients with chronic... | May 4, 2023
May 3, 2023
Managements Discussion and Analysis of Financial Condition and Results of Operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with... | May 3, 2023
May 2, 2023
StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research report report published on Saturday morning. The firm issued a buy rating on the biopharmaceutical company’s stock. Acorda Therapeutics Price Performance NASDAQ ACOR opened at $0.47 on Friday. The business’s fifty day moving average price is $0.65 and its 200-day […]
April 26, 2023
The Peace Accords Matrix at the University of Notre Dame’s Kroc Institute for International Peace Studies has released a new special report o...